ICCM — Icecure Medical Income Statement
0.000.00%
Last trade - 00:00- $66.19m
- $58.62m
- $3.29m
Annual income statement for Icecure Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.87 | 4.14 | 3.08 | 3.23 | 3.29 |
| Cost of Revenue | |||||
| Gross Profit | 2.44 | 2.19 | 1.45 | 1.3 | 1.45 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 8.01 | 13.9 | 19.8 | 18.8 | 19 |
| Operating Profit | -4.14 | -9.72 | -16.7 | -15.6 | -15.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.73 | -9.89 | -17 | -14.7 | -15.3 |
| Net Income After Taxes | -3.73 | -9.89 | -17 | -14.7 | -15.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.73 | -9.89 | -17 | -14.7 | -15.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.73 | -9.89 | -17 | -14.7 | -15.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.218 | -0.347 | -0.459 | -0.321 | -0.301 |
| Dividends per Share |